Serina Therapeutics (SER) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Cover [Abstract]
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,935,088
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021		Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 809,000		$ 527,000
Accounts and grants receivable, net	48,000		326,000
Prepaid expenses and other current assets	1,285,000		1,430,000
Total current assets	2,142,000		2,283,000
Deposits and other long-term assets	50,000		50,000
Intangible assets, net	968,000		1,592,000
TOTAL ASSETS	3,160,000		3,925,000
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,198,000	[1]	1,656,000
Loan due to Juvenescence, net of debt issuance cost, current portion	2,020,000		1,960,000
Related party payables, net	71,000		71,000
Deferred revenues, current portion			275,000
Paycheck Protection Program Loan			436,000
Insurance premium liability and other current liabilities	640,000		959,000
Total current liabilities	3,929,000		5,357,000
Loan due to Juvenescence, net of debt issuance cost, net of current portion	5,334,000		3,900,000
Deferred revenues, net of current portion			64,000
TOTAL LIABILITIES	9,263,000		9,321,000
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of March 31, 2021 and December 31, 2020
Common stock, $0.0001 par value, 100,000 shares authorized; and 37,935 and 37,691 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	4,000		4,000
Additional paid-in capital	93,095,000		91,810,000
Accumulated other comprehensive income			143,000
Accumulated deficit	(99,161,000)		(97,073,000)
AgeX Therapeutics, Inc. stockholders' deficit	(6,062,000)		(5,116,000)
Noncontrolling interest	(41,000)		(280,000)
Total stockholders' deficit	(6,103,000)		(5,396,000)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,160,000		$ 3,925,000
[1]	Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,935,000	37,691,000
Common stock, shares outstanding	37,935,000	37,691,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenues	$ 56	$ 89
Cost of sales	(3)	(1)
Gross profit	53	88
Research and development	324	1,221
General and administrative	2,022	1,875
Total operating expenses	2,346	3,096
Gain on deconsolidation of LifeMap Sciences (see Note 3)	106
Loss from continuing operations before interest and other income (expense), net	(2,187)	(3,008)
Interest expense, net	(243)	(30)
Other income, net	437	5
Loss from continuing operations	(1,993)	(3,033)
Loss from discontinued operations (see Note 3)	(103)	(189)
NET LOSS	(2,096)	(3,222)
Net loss attributable to noncontrolling interest from continuing operations	1
Net loss attributable to noncontrolling interest from discontinued operations	7	35
NET LOSS ATTRIBUTABLE TO AGEX	$ (2,088)	$ (3,187)
NET LOSS PER COMMON SHARE: BASIC AND DILUTED
Continuing operations	$ (0.05)	$ (0.08)
Discontinued operations	(0.01)	0
BASIC AND DILUTED	$ (0.06)	$ (0.08)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED	37,729,000	37,651,000
AMOUNTS ATTRIBUTABLE TO AGEX:
Loss from continuing operations	$ (1,992)	$ (3,033)
Loss from discontinued operations	(96)	(154)
NET LOSS ATTRIBUTABLE TO AGEX	(2,088)	(3,187)
Grant Revenues [Member]
Total revenues	46	86
Other Revenues [Member]
Total revenues	$ 10	$ 3

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
NET LOSS	$ (2,096)	$ (3,222)
Other comprehensive expense, net of tax:
Foreign currency translation adjustments from discontinued operations	(143)	(25)
COMPREHENSIVE LOSS	(2,239)	(3,247)
Less: Comprehensive loss attributable to noncontrolling interest	8	35
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS	$ (2,231)	$ (3,212)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to AgeX	$ (1,992)	$ (3,033)
Net loss attributable to noncontrolling interest	(1)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on deconsolidation of LifeMap Sciences (see Note 3)	(106)
Forgiveness of Paycheck Protection Program Loan and accumulated interest	(437)
Depreciation expense		123
Amortization of intangible assets	33	33
Amortization of right-of-use asset		104
Amortization of debt issuance cost	267	47
Stock-based compensation	178	252
Changes in operating assets and liabilities:
Accounts and grants receivable, net	105	11
Prepaid expenses and other current assets	117	201
Accounts payable and accrued liabilities	(346)	345
Related party payables		117
Insurance premium liability	(304)	(314)
Other current liabilities	(54)	(128)
Net cash used in operating activities from continuing operations	(2,540)	(2,240)
Net cash provided by (used in) operating activities from discontinued operations (see Note 3)	(90)	176
Net cash used in operating activities	(2,630)	(2,064)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of LifeMap Sciences	466
Purchase of equipment		(4)
Net cash provided by (used in) investing activities from continuing operations	466	(4)
Deconsolidation of cash and cash equivalents from discontinued operations (see Note 3)	(50)
Net cash provided by (used in) investing activities	416	(4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Draw down on loan facility from Juvenescence	2,000	200
Proceeds from the issuance of common stock	496
Partial collection on loan due from LifeMap Sciences	250
Repayment of financing lease liability		(15)
Net cash provided by financing activities from continuing operations	2,746	185
Partial payment on loan due to AgeX from discontinued operations (see Note 3)	(250)
Net cash provided by financing activities	2,496	185
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(1)
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	282	(1,884)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period	577	2,452
At end of the period	$ 859	$ 568

Organization, Business Overview

Organization, Business Overview and Liquidity	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Business Overview and Liquidity	1. Organization, Business Overview and Liquidity AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are: ● PureStem ® ● UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells; ● AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes; ● AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and ● Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair. Emerging Growth Company AgeX is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012. Disposition and deconsolidation of LifeMap Sciences As discussed in Note 3, AgeX received approximately $466,400 in cash as its pro rata share of the Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock. As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Accordingly, AgeX has deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from AgeX, effective March 15, 2021 (the “LifeMap Deconsolidation”), in accordance with Accounting Standards Codification, or ASC 810-10-40-4(c), Consolidation Going Concern AgeX primarily finances its operations through sales of its common stock, loans from its largest stockholder Juvenescence Limited (“Juvenescence”), and research grants. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $99.2 million as of March 31, 2021. AgeX expects to continue to incur operating losses and negative cash flows. Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have made certain adjustments to AgeX’s operating plans and budgets, including the staff reductions discussed below, to reduce its projected cash expenditures to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those adjustments, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.8 million as of March 31, 2021 plus the loan facility by Juvenescence to advance up to an additional $4.5 million to AgeX for operating capital discussed in Note 5, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these condensed consolidated interim financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. Staff Reductions and Elimination of Laboratory Facilities Lease During April 2020, AgeX initiated staff layoffs that affected 11 research and development personnel. AgeX paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $195,000 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits. The staff reductions followed AgeX’s strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic. Following the staff reductions, AgeX subleased out a significant portion of its leased laboratory space and did not renew its lease or enter into a new lease for a replacement facility when its lease expired on December 31, 2020. Instead, AgeX entered into a lease for a smaller office only space commencing January 1, 2021. Liquidity and impact of COVID-19 In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in development of its product candidates and technologies. The availability of financing may be adversely impacted by the COVID-19 pandemic which could continue to depress national and international economies and disrupt capital markets, supply chains, and aspects of AgeX’s operations. he extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s condensed consolidated balance sheets. AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at March 31, 2021, due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations AgeX’s unaudited consolidated statements of operations for the three months ended March 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day. For the three months ended March 31, 2020, AgeX’s unaudited consolidated results include LifeMap Sciences’ consolidated results for the full period presented. AgeX has one operating subsidiary, ReCyte Therapeutics, Inc. (“ReCyte”). ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. All material intercompany accounts and transactions have been eliminated in consolidation. Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertisement revenues ® ® LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers For the period three months ended March 31, 2021 and 2020, LifeMap Sciences recognized $267,000 and $338,000, respectively in subscription and advertisement revenues which are included in operating loss from discontinued operations. The LifeMap Sciences revenues for the three months ended March 31, 2021 are for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3 for further information on the disposition and deconsolidation of LifeMap Sciences. Grant revenues – Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provided funding for continued development of AgeX technologies for treating osteoporosis. Grant funds were made available by the NIH as allowable expenses were incurred. For the three month ended 2020, AgeX incurred approximately $25,000, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. As of March 31, 2020, AgeX expended the full amount available under the grant. On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the NIH. The NIH grant provides funding for continued development of AgeX’s technologies for treating stroke. The grant funds will be made available by the NIH to AgeX as allowable expenses are incurred. For the three months ended March 31, 2021 and 2020, AgeX incurred approximately $46,000 and $61,000, respectively, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. Arrangements with multiple performance obligations – Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations. General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three months ended March 31, 2021 and 2020, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Three Months Ended March 31, 2021 2020 Stock options 2,851 2,846 Warrants (1) 3,431 150 Restricted stock units 27 47 (1) AgeX issued Juvenescence warrants to purchase 3,512,098 shares of AgeX common stock as consideration for the line of credit under the Loan Agreements discussed in Note 5. Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net and operating lease liability on its balance sheet in accordance with ASC 842 up until the lease terminated on December 31, 2020 (see Note 10). During 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. This lease is not subject to ASC 842. Reclassifications Certain reclassifications have been made to the prior years’ consolidated financial statements to conform to current year presentation of discontinued operations. Certain financial information is presented on a rounded basis, which may cause minor differences. Recently adopted accounting pronouncement In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. On August 5, 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 10, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act.

Disposition and Deconsolidation

Disposition and Deconsolidation of LifeMap Sciences	3 Months Ended
	Mar. 31, 2021
Insurance [Abstract]
Disposition and Deconsolidation of LifeMap Sciences	3. Disposition and Deconsolidation of LifeMap Sciences Discontinued Operations On March 6, 2021, AgeX and LifeMap Sciences entered into the Merger Agreement with Atlas and GCLMS. On March 15, 2021, the merger was completed pursuant to the terms of the Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of the $500,000 total Merger Consideration, with each LifeMap Sciences shareholder’s pro rata portion of the Merger Consideration determined in accordance with the number of shares of LifeMap Sciences common stock owned by such shareholder as a percentage of shares of LifeMap Sciences common stock outstanding immediately before the effective date of the merger, and (b) the outstanding shares of GCLMS common stock were converted into shares of LifeMap Sciences common stock so that Atlas is now the sole shareholder of LifeMap Sciences. AgeX received approximately $466,400 in cash as its pro rata share of the Merger Consideration in the merger. Prior to and as a condition to the merger under the terms of the Merger Agreement, $1,761,296 of LifeMap Sciences’ indebtedness to AgeX was converted into shares of LifeMap Sciences common stock. LifeMap Sciences also paid AgeX $250,000 in cash to pay off a portion of LifeMap Sciences’ indebtedness to AgeX that was not converted into shares of LifeMap Sciences common stock. The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under US generally accepted accounting principles in accordance with ASC 205-20 Discontinued Operations Three Months Ended March 31, 2021 March 31, 2020 Net revenues $ 277 $ 426 Costs, operating and other expenses (380 ) (615 ) Loss from discontinued operations (103 ) (189 ) Net loss from discontinued operations attributable to noncontrolling interest 7 35 Loss from discontinued operations (1) $ (96 ) $ (154 ) (1) Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement line item Net (gain) loss on sales of businesses and assets. Deconsolidation As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Effective March 15, 2021, AgeX deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from those of AgeX under US generally accepted accounting principles ASC 810-10-40-4 Deconsolidation of a Subsidiary or Derecognition of a Group of Assets AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at March 31, 2021, due to the LifeMap Deconsolidation AgeX’s unaudited consolidated statements of operations for the three months ended March 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the LifeMap Deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day. For the three months ended March 31, 2020, AgeX’s unaudited consolidated results include LifeMap Sciences’ consolidated results for the full period presented. AgeX recognized a gain of $106,000 from the LifeMap Deconsolidation. The sale of LifeMap Sciences was a taxable transaction to AgeX, however no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX's tax basis in the subsidiary.

Selected Balance Sheet Componen

Selected Balance Sheet Components	3 Months Ended
	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Selected Balance Sheet Components	4. Selected Balance Sheet Components Property and equipment, net At March 31, 2021 and December 31, 2020, property and equipment was comprised of the following (in thousands): March 31, 2021 (unaudited) December 31, 2020 Equipment, furniture and fixtures $ 381 $ 381 Accumulated depreciation and amortization (381 ) (381 ) Property and equipment, net $ - $ - Depreciation and amortization expense amounted to nil and $227,000 for the three months ended March 31, 2021 and 2020, respectively. Intangible assets, net At March 31, 2021 and December 31, 2020, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): March 31, 2021 (unaudited) (1) December 31, 2020 Intangible assets $ 1,312 $ 5,586 Accumulated amortization (344 ) (3,994 ) Total intangible assets, net $ 968 $ 1,592 AgeX recognized $33,000 in amortization expense of intangible assets, included in research and development expenses, for the three months ended March 31, 2021 and 2020. Amortization expense of intangible assets for discontinued operations for the three months ended March 31, 2021 and 2020 amounted to $89,000 and $107,000. (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3. Accounts payable and accrued liabilities At March 31, 2021 and December 31, 2020, accounts payable and accrued liabilities were comprised of the following (in thousands): March 31, 2021 (unaudited) (1) December 31, 2020 Accounts payable $ 370 $ 761 Accrued compensation 212 228 Accrued vendors and other expenses 616 667 Total accounts payable and accrued liabilities $ 1,198 $ 1,656 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions Transactions with Juvenescence On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence has agreed to provide to AgeX an $8.0 million line of credit for a period of 18 months on substantially the same terms as the Loan Agreement described below, except that (a) all loans to AgeX under the 2020 Loan Agreement in excess of an initial $500,000 advance are subject to Juvenescence’s discretion, (b) AgeX may not draw more than $1 million in any single draw, (c) in lieu of accrued interest, AgeX issued to Juvenescence 28,500 shares of AgeX common stock when AgeX borrowed an aggregate of $3 million under the 2020 Loan Agreement, (d) AgeX will issue to Juvenescence warrants to purchase shares of AgeX common stock (“New Warrants”) in amounts determined by the warrant formula described below, (e) the Repayment Date for outstanding principal balance of the loan under the 2020 Loan Agreement will be March 30, 2023, (f) AgeX agreed to enter into a Security and Pledge Agreement (the “Security Agreement”) granting Juvenescence a security interest in all of the assets of AgeX and AgeX’s subsidiaries ReCyte Therapeutics and Reverse Bioengineering, Inc. (the “Guarantor Subsidiaries” or each a “Guarantor Subsidiary”) (g) the Guarantor Subsidiaries agreed to guarantee AgeX’s obligations under the 2020 Loan Agreement, and (h) Juvenescence has the right to convert the principal amount of outstanding loans under the 2020 Loan Agreement into shares of AgeX common stock at the Market Price as defined in the 2020 Loan Agreement. Further, in addition to the Events of Default described herein, additional Events of Default will arise under the 2020 Loan Agreement if (i) AgeX or any of the Guarantor Subsidiaries sells, leases, licenses, consigns, transfers, or otherwise disposes of a material part of its assets other than inventory in the ordinary course of business or certain intercompany transactions, or certain other limited permitted transactions, unless Juvenescence approves, (ii) the security interests under the Security Agreement, if in effect, are not valid or perfected, or AgeX or a Guarantor Subsidiary contests the validity of its obligations under the 2020 Loan Agreement or Security Agreement or other related agreement with Juvenescence, or there is a loss, theft, damage or destruction of a material portion of the collateral, (iii) any representation, warranty, or other statement made by AgeX or a Guarantor Subsidiary under the 2020 Loan Agreement is incomplete, untrue, incorrect, or misleading, or (iv) AgeX or a Guarantor Subsidiary suspends or ceases to carry on all or a material part of its business or threatens to do so. On July 21, 2020, AgeX and Juvenescence entered into an amendment to the 2020 Loan Agreement that waived (i) certain provisions requiring that, as a condition to the funding of a third draw of funds, AgeX and the Guarantor Subsidiaries execute a Security Agreement and related documents pledging certain assets as collateral, and (ii) certain provisions providing that the Guarantor Subsidiaries would guarantee AgeX’s obligations under the 2020 Loan Agreement, in each case subject to an acknowledgement by AgeX and the Guarantor Subsidiaries that Juvenescence may, in its discretion, condition any advances under the 2020 Loan Agreement subsequent to the third draw of funds on the receipt of such collateral agreements and guarantees. In addition, the 2020 Loan Agreement and the related Warrant Agreement were amended to place certain limits on the number of shares that may be issued to Juvenescence upon conversion of outstanding loan amounts or exercise of the warrants, in order to comply with applicable NYSE American listing requirements. During January 2021, AgeX borrowed an additional $2.0 million under the 2020 Loan Agreement with Juvenescence. Through March 31, 2021, AgeX drew a total of $7.5 million against the $8.0 million line of credit. AgeX may draw additional funds from time to time subject to Juvenescence’s discretion, prior to the Repayment Date on March 30, 2023. AgeX may not draw down funds if an “Event of Default” under the 2020 Loan Agreement has occurred and is continuing and AgeX may not draw down more than $1.0 million in any single draw. On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit for a period of 18 months. As of March 31, 2021, AgeX had drawn the full $2.0 million line of credit. In lieu of accrued interest, AgeX issued to Juvenescence 19,000 shares of AgeX common stock, with an approximate value of $56,000, concurrently with the first draw down of funds under the Loan Agreement. However, if AgeX fails to repay the loan when due, interest at the rate of 10% per annum, compounded daily, will accrue on the unpaid balance from the date the payment was due. In lieu of repayment of funds borrowed, AgeX or Juvenescence may convert the loan balance (including principal and accrued interest, if any) into AgeX common stock or “units” if AgeX consummates a “Qualified Offering” which means a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $7.5 million. Events of Default under the Loan Agreement include: (i) AgeX fails to pay any amount in the manner and at the time provided in the Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due; (iv) AgeX stops payment of its debts generally or discontinues its business or becomes unable to pay its debts as they become due or enters into any arrangement with creditors generally, (v) AgeX becoming insolvent or in liquidation or administration or other insolvency procedures, or a receiver, trustee or similar officer is appointed in respect of all or any part of its assets and such appointment continues undischarged or unstayed for sixty days, (vi) it becomes illegal for AgeX to perform its obligations under the Loan Agreement or any governmental permit, license, consent, exemption or similar requirement for AgeX to perform its obligations under the Loan Agreement or to carry out its business is not obtained or ceases to remain in effect; (vii) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX if such process is not released, vacated or fully bonded within sixty calendar days after its issue or levy; (viii) any injunction, order or judgement of any court is entered or issued which in the opinion of Juvenescence materially and adversely affects the ability of AgeX to carry out its business or to pay amounts owed to Juvenescence under the Loan Agreement, and (ix) there is a change in AgeX’s financial condition that in the opinion of Juvenescence materially and adversely affects, or is likely to so affect, its ability to perform any of its obligations under the Loan Agreement. As consideration for the line of credit under the Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 shares of AgeX common stock. The exercise price of the warrants is $2.60 per share, which was the volume weighted average price on the NYSE American (VWAP) of AgeX common stock over the twenty trading days prior to the date the warrants were issued. The warrants will expire at 5:00 p.m. New York time three years after the date of issue. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events. The estimated value of these warrants was $236,000 which was determined in accordance with the Black-Scholes option pricing model with inputs as specified in the relevant warrant agreement. On February 10, 2021, AgeX entered into an amendment (the “Amendment”) to the 2019 Loan Agreement. The Amendment extends the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 and increases the amount of the loan facility by $4.0 million. All loans in excess of the initial $2.0 million under the 2019 Loan Agreement that AgeX previously borrowed are subject to Juvenescence’s discretion. Additional loans, if made, will be in denominations of $1.0 million. No withdrawals were made against the $4.0 million as of March 31, 2021. The Amendment also grants Juvenescence the right to convert the principal amount of outstanding loans under the 2019 Loan Agreement, as amended, into shares of AgeX common stock at the Market Price as defined in the Amendment. The Amendment places certain limits on the number of shares that may be issued upon conversion of outstanding loan amounts by Juvenescence, or by AgeX under AgeX’s loan conversion rights, if under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of the shares. Under those limits (a) the number of shares of common stock that may be issued upon conversion of any loan advance, at a conversion price that is lower than the market price of AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence’s ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding. AgeX will pay Juvenescence an Origination Fee in the amount of $160,000 upon the earlier of the repayment of the loan by AgeX or the conversion of the loan balance into AgeX common stock by Juvenescence or by AgeX. The Origination Fee will be paid in shares of AgeX common stock rather than cash if AgeX exercises its right to convert the loan into shares of common stock, or if Juvenescence elects to convert the loan in shares of common stock and elects to receive the Origination Fee in AgeX common stock. AgeX has entered into a Registration Rights Agreement, as amended, to use commercially reasonable efforts to register the shares issuable under the Loan Agreement and New Loan Agreement, the warrants issued pursuant to the 2019 Loan Agreement, the New Warrants, and the shares issuable upon the exercise of those warrants, and shares issuable upon conversion of the loans under the 2019 Loan Agreement and 2020 Loan Agreement into common stock (collectively, the “Registrable Securities”) for resale under the Securities Act of 1933, as amended (the “Securities Act”), upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of warrants or shares. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. During January 2021 AgeX registered Registrable Securities consisting of 19,695,746 shares of AgeX common stock. Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. As of March 31, 2021 and December 31, 2020, AgeX had approximately $71,000 payable to Juvenescence for COO services rendered, included in related party payables, net, on the condensed consolidated balance sheets.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity (Deficit)	6. Stockholders’ Equity (Deficit) Preferred Stock AgeX is authorized to issue up to 5,000,000 shares of $0.0001 par value preferred stock. At March 31, 2021 there were no preferred shares issued and outstanding. Common Stock AgeX has 100,000,000 shares of $0.0001 par value common stock authorized. At March 31, 2021 and December 31, 2020, there were 37,935,088 and 37,691,047 shares of AgeX common stock issued and outstanding, respectively. Issuance and Sale of Warrants by AgeX Through March 31, 2021, as consideration for $7.5 million in loans made to AgeX under the 2020 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 3,362,098 shares of AgeX common stock. AgeX also issued 28,500 shares of AgeX common stock upon receipt of funds from the loan draw made on July 27, 2020. See Note 5. On August 13, 2019, in lieu of accrued interest under the Loan Agreement, AgeX issued to Juvenescence 19,000 shares of AgeX common stock concurrently with the first draw down of loan funds. Furthermore, as consideration for the line of credit under the Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 shares of AgeX common stock. See Note 5. At-the-Market Offering Facility On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets LLC (“Chardan”), relating to the sale of shares of AgeX common stock, par value $0.0001 per share, through an at-the-market (“ATM”) offering as described in the prospectus supplement filed with the Form S-3 which was declared effective by the SEC on January 29, 2021. In accordance with the terms of the sales agreement, AgeX may offer and sell shares of AgeX common stock having an aggregate offering price of up to $12.6 million from time to time through Chardan, acting as the sales agent. Through March 31, 2021, AgeX raised approximately $496,000 in gross proceeds through the sale of shares of common stock under the ATM. Reconciliation of Changes in Stockholders’ Equity (Deficit) The following tables provide the activity in stockholders’ equity (deficit) for the three months ended March 31, 2021 and 2020 (unaudited and in thousands): Common Stock Accumulated Total Number Par Additional Accumulated Noncontrolling Other Stockholders’ BALANCE AT DECEMBER 31, 2020 37,691 $ 4 $ 91,810 $ (97,073 ) $ (280 ) $ 143 $ (5,396 ) Issuance of common stock 242 - 475 - - - 475 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (3 ) - - - (3 ) Issuance of warrants - - 757 - - - 757 Stock-based compensation - - 182 - - - 182 Transactions with noncontrolling interests – LifeMap Sciences - - (269 ) - 269 - - Deconsolidation of LifeMap Sciences - - 143 - (22 ) (143 ) (22 ) Net loss - - - (2,088 ) (8 ) - (2,096 ) BALANCE AT MARCH 31, 2021 37,935 $ 4 $ 93,095 $ (99,161 ) $ (41 ) $ - $ (6,103 ) Common Stock Accumulated Total Number Par Additional Accumulated Noncontrolling Other Stockholders’ BALANCE AT DECEMBER 31, 2019 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 7 - (5 ) - - - (5 ) Stock-based compensation - - 260 - - 260 Foreign currency translation adjustment - - - - - (25 ) (25 ) Net loss - - - (3,187 ) (35 ) - (3,222 ) BALANCE AT MARCH 31, 2020 37,656 $ 4 $ 88,608 $ (89,395 ) $ 364 $ 44 $ (375 )

Stock-Based Awards

Stock-Based Awards	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Awards	7. Stock-Based Awards Equity Incentive Plan Awards AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of 4,000,000 shares of common stock are available for the grant of stock options, the sale of restricted stock, the settlement of restricted stock units, and the grant of stock appreciation rights. The Plan also permits AgeX to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine. A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Shares Number Number Weighted December 31, 2020 1,046 2,854 28 $ 2.51 Options forfeited 14 (14 ) - 3.00 Restricted stock units vested - - (3 ) - March 31, 2021 1,060 2,840 25 $ 2.51 Options exercisable at March 31, 2021 2,035 $ 2.61 There have been no exercises of stock options to date. Stock-based Compensation Expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. No stock options were granted under the Plan during the three months ended March 31, 2021 and 2020. Operating expenses include stock-based compensation expense as follows (unaudited and in thousands): Three Months Ended 2021 2020 Research and development $ 16 $ 33 General and administrative 162 220 Total stock-based compensation expense – continued operations $ 178 $ 253 Stock-based compensation expense recognized under discontinued operations for the three months ended March 31, 2021 and 2020 amounted to $4,000 and $7,000, respectively. See Note 3.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where AgeX conducts business. Beginning in 2018, the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”) subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50% of GILTI, however this deduction is limited to the company’s pre-GILTI U.S. income. For the year ended December 31, 2020, AgeX’s foreign entity operated at a book loss, however, for GILTI, US tax laws are applied to the foreign activity, as a result there was an immaterial inclusion amount. For the three months ended March 31, 2021, AgeX’s foreign entity operated at a loss, therefore no GILTI was included in income for the first quarter of 2021. Current interpretations under ASC 740 state that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. We have elected to account for GILTI as a current period expense when incurred. For the three months ended March 31, 2021, AgeX experienced a domestic loss from continuing operations and a foreign loss; therefore, no income tax provision was recorded for the three months ended March 31, 2021. The sale of LifeMap Sciences was a taxable transaction to AgeX, however no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX's tax basis in the subsidiary. Due to losses incurred for all periods presented, AgeX did not record a domestic provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its domestic deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	9. Supplemental Cash Flow Information Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are as follows (unaudited and in thousands): Three Months Ended 2021 2020 Supplemental disclosures of non-cash investing and financing activities: Cash paid during the period for interest $ 7 $ 7 Issuance of common stock upon vesting of restricted stock units (Note 6) $ 6 $ 11 Issuance of warrants for debt issuance $ 757 $ -

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Lease Agreement On April 2, 2019, the term of a sublease that AgeX entered into during March 2019 (the “AgeX Lease”) went into effect for an office and research facility (the “Alameda Facility”) comprising approximately 23,911 square feet of space in a building in an office and research park at 965 Atlantic Avenue, Alameda, California that served as AgeX’s principal offices and research laboratory. Base monthly rent was $35,866.50 for the initial 12 months of the sublease term and then increased to $36,942.50. In addition, AgeX paid real property taxes, insurance and operating expenses pertaining to the building in which the Alameda Facility is located. The AgeX Lease expired on December 31, 2020. In connection with the AgeX Lease, as of December 31, 2019, AgeX incurred $436,000 in tenant improvement expenses that it funded and completed in November 2019. This amount was fully amortized and written off upon lease termination as of December 31, 2020. Subleases During 2019, AgeX, as a sublessor, entered into sublease agreements (the “AgeX Subleases”) with unrelated parties (the “Sublessees”) to lease approximately 11,121 square feet of space at AgeX’s Alameda Facility. The first Sublessee paid AgeX $3,088.50 per month and the second Sublessee paid AgeX $15,405.40 per month for the first twelve months of the AgeX Sublease and $16,311.60 per month for the remaining duration of the AgeX Subleases. The AgeX Subleases expired on December 31, 2020. Office Lease Agreement Effective January 1, 2021, AgeX relocated its principal offices to 1101 Marina Village Parkway, Suite 201, Alameda, California following the December 31, 2020 expiration of the Alameda Lease. AgeX’s new office occupies 135 square feet of leased space in a building located in an office and research park. Base monthly rent is $947 for the one year lease term and also covers office furniture rental, janitorial services, utilities and internet service. ASC 842 AgeX adopted ASC 842 in 2019. AgeX recorded a right-of-use asset of $726,000 and a right-of-use liability for the same amount for the AgeX Lease in April 2019, which is considered a noncash investing activity. The right-of-use asset and right-of-use lease liability were fully amortized and written off as of December 31, 2020 upon termination of the AgeX Lease. There were no future minimum lease commitments as of March 31, 2021. Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. Indemnification In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s pre-clinical programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s pre-clinical programs. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to AgeX’s pre-clinical programs. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular research, development, services, license, or lease agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements to date. PPP Loan On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank (the “Bank”) under the Paycheck Protection Program (the “PPP Loan”). The PPP loan will bear interest at a rate of 1% per annum. No payments will be due on the PPP loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP loan was subject to forgiveness under the PPP to the extent of PPP loan proceeds that were used to pay expense permitted by the PPP, including payroll, rent, and utilities during the time frame permitted by the PPP. On February 19, 2021, the PPP loan was forgiven in full. On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law, retroactively allowing a federal deduction of the expenses that gave rise to the PPP loan forgiveness. California does not allow a deduction for these expenses for publicly traded companies. An analysis has been performed through March 31, 2021 and the appropriate expenses have been disallowed for California income tax purposes, as a result, we do not expect any material changes. Notice of Delisting On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan. On April 15, 2021 AgeX regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the Exchange Company Guide. Specially, the Exchange has resolved the continued listing deficiency with respect to Section 1003(a)(i) of the Exchange Company Guide. AgeX however will be subject to normal continued listing monitoring. If AgeX is again determined to be below any of the continued listing standards within 12 months of April 15, 2021, the Exchange may take action, including truncating the compliance procedures described in Section 1009 of the Exchange Company Guide or immediately initiating delisting proceedings. AgeX intends to make arrangements to have its common stock quoted on the OTC Bulletin Board if its common stock is delisted from the Exchange.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events Additional Draws under the 2019 Loan Agreement as Amended in February 2021 On April 23, 2021, AgeX borrowed an additional $500,000 under the Amended 2019 Loan Agreement with Juvenescence. The outstanding principal balance of the loans under the Amended 2019 Loan Agreement will become due and payable on the Repayment Date on February 14, 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s condensed consolidated balance sheets. AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at March 31, 2021, due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations AgeX’s unaudited consolidated statements of operations for the three months ended March 31, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $1,761,296 of LifeMap Sciences’ indebtedness to AgeX into shares of LifeMap Sciences common stock on March 15, 2021 followed by the completion of the cash-out merger on the same day. For the three months ended March 31, 2020, AgeX’s unaudited consolidated results include LifeMap Sciences’ consolidated results for the full period presented. AgeX has one operating subsidiary, ReCyte Therapeutics, Inc. (“ReCyte”). ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8% of the outstanding capital stock of ReCyte. All material intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertisement revenues ® ® LifeMap Sciences has licensed from third parties the databases and software it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers For the period three months ended March 31, 2021 and 2020, LifeMap Sciences recognized $267,000 and $338,000, respectively in subscription and advertisement revenues which are included in operating loss from discontinued operations. The LifeMap Sciences revenues for the three months ended March 31, 2021 are for revenues earned through March 15, 2021. As a result of the LifeMap Deconsolidation, AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods. See Note 3 for further information on the disposition and deconsolidation of LifeMap Sciences. Grant revenues – Research and Development Arrangements In September 2018, AgeX was awarded a grant of up to approximately $225,000 from the National Institutes of Health (NIH). The NIH grant provided funding for continued development of AgeX technologies for treating osteoporosis. Grant funds were made available by the NIH as allowable expenses were incurred. For the three month ended 2020, AgeX incurred approximately $25,000, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. As of March 31, 2020, AgeX expended the full amount available under the grant. On April 8, 2020, AgeX was awarded a grant of up to approximately $386,000 from the NIH. The NIH grant provides funding for continued development of AgeX’s technologies for treating stroke. The grant funds will be made available by the NIH to AgeX as allowable expenses are incurred. For the three months ended March 31, 2021 and 2020, AgeX incurred approximately $46,000 and $61,000, respectively, of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. Arrangements with multiple performance obligations –
Research and Development	Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.
General and Administrative	General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.
Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three months ended March 31, 2021 and 2020, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Three Months Ended March 31, 2021 2020 Stock options 2,851 2,846 Warrants (1) 3,431 150 Restricted stock units 27 47 (1) AgeX issued Juvenescence warrants to purchase 3,512,098 shares of AgeX common stock as consideration for the line of credit under the Loan Agreements discussed in Note 5.
Leases	Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net and operating lease liability on its balance sheet in accordance with ASC 842 up until the lease terminated on December 31, 2020 (see Note 10). During 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. This lease is not subject to ASC 842.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior years’ consolidated financial statements to conform to current year presentation of discontinued operations. Certain financial information is presented on a rounded basis, which may cause minor differences.
Recently Adopted Accounting Pronouncement	Recently adopted accounting pronouncement In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. On August 5, 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)
CARES Act	CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 10, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Three Months Ended March 31, 2021 2020 Stock options 2,851 2,846 Warrants (1) 3,431 150 Restricted stock units 27 47 (1) AgeX issued Juvenescence warrants to purchase 3,512,098 shares of AgeX common stock as consideration for the line of credit under the Loan Agreements discussed in Note 5.

Disposition and Deconsolidati_2

Disposition and Deconsolidation of LifeMap Sciences (Tables)	3 Months Ended
	Mar. 31, 2021
Insurance [Abstract]
Schedule of Discontinued Operations	The following table presents the operating results of LifeMap Sciences that have been treated as discontinued operations for the periods presented (unaudited and in thousands): Three Months Ended March 31, 2021 March 31, 2020 Net revenues $ 277 $ 426 Costs, operating and other expenses (380 ) (615 ) Loss from discontinued operations (103 ) (189 ) Net loss from discontinued operations attributable to noncontrolling interest 7 35 Loss from discontinued operations (1) $ (96 ) $ (154 ) (1) Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement line item Net (gain) loss on sales of businesses and assets.

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment, Net,	At March 31, 2021 and December 31, 2020, property and equipment was comprised of the following (in thousands): March 31, 2021 (unaudited) December 31, 2020 Equipment, furniture and fixtures $ 381 $ 381 Accumulated depreciation and amortization (381 ) (381 ) Property and equipment, net $ - $ -
Schedule of Intangible Assets, Net	At March 31, 2021 and December 31, 2020, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): March 31, 2021 (unaudited) (1) December 31, 2020 Intangible assets $ 1,312 $ 5,586 Accumulated amortization (344 ) (3,994 ) Total intangible assets, net $ 968 $ 1,592
Schedule of Accounts Payable and Accrued Liabilities	At March 31, 2021 and December 31, 2020, accounts payable and accrued liabilities were comprised of the following (in thousands): March 31, 2021 (unaudited) (1) December 31, 2020 Accounts payable $ 370 $ 761 Accrued compensation 212 228 Accrued vendors and other expenses 616 667 Total accounts payable and accrued liabilities $ 1,198 $ 1,656 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Reconciliation Changes in Stockholders' Equity	The following tables provide the activity in stockholders’ equity (deficit) for the three months ended March 31, 2021 and 2020 (unaudited and in thousands): Common Stock Accumulated Total Number Par Additional Accumulated Noncontrolling Other Stockholders’ BALANCE AT DECEMBER 31, 2020 37,691 $ 4 $ 91,810 $ (97,073 ) $ (280 ) $ 143 $ (5,396 ) Issuance of common stock 242 - 475 - - - 475 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (3 ) - - - (3 ) Issuance of warrants - - 757 - - - 757 Stock-based compensation - - 182 - - - 182 Transactions with noncontrolling interests – LifeMap Sciences - - (269 ) - 269 - - Deconsolidation of LifeMap Sciences - - 143 - (22 ) (143 ) (22 ) Net loss - - - (2,088 ) (8 ) - (2,096 ) BALANCE AT MARCH 31, 2021 37,935 $ 4 $ 93,095 $ (99,161 ) $ (41 ) $ - $ (6,103 ) Common Stock Accumulated Total Number Par Additional Accumulated Noncontrolling Other Stockholders’ BALANCE AT DECEMBER 31, 2019 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 7 - (5 ) - - - (5 ) Stock-based compensation - - 260 - - 260 Foreign currency translation adjustment - - - - - (25 ) (25 ) Net loss - - - (3,187 ) (35 ) - (3,222 ) BALANCE AT MARCH 31, 2020 37,656 $ 4 $ 88,608 $ (89,395 ) $ 364 $ 44 $ (375 )

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Shares Number Number Weighted December 31, 2020 1,046 2,854 28 $ 2.51 Options forfeited 14 (14 ) - 3.00 Restricted stock units vested - - (3 ) - March 31, 2021 1,060 2,840 25 $ 2.51 Options exercisable at March 31, 2021 2,035 $ 2.61
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (unaudited and in thousands): Three Months Ended 2021 2020 Research and development $ 16 $ 33 General and administrative 162 220 Total stock-based compensation expense – continued operations $ 178 $ 253

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are as follows (unaudited and in thousands): Three Months Ended 2021 2020 Supplemental disclosures of non-cash investing and financing activities: Cash paid during the period for interest $ 7 $ 7 Issuance of common stock upon vesting of restricted stock units (Note 6) $ 6 $ 11 Issuance of warrants for debt issuance $ 757 $ -

Organization, Business Overvi_2

Organization, Business Overview and Liquidity (Details Narrative)	Mar. 15, 2021USD ($)	Mar. 06, 2021USD ($)	Apr. 30, 2020USD ($)Integer	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Accumulated deficit				$ 99,161,000	$ 97,073,000
Cash and cash equivalents				809,000	$ 527,000
Number of staff layoffs | Integer			11
Accrued payroll			$ 105,000
Restructuring charges			$ 195,000
Merger Agreement [Member]
Payment of merger consideration on pro rata portion		$ 466,400
Conversion of shares of common stock, value		250,000
Indebtedness cash	$ 1,761,926	1,761,296
LifeMap Sciences, Inc. [Member] | Merger Agreement [Member]
Payment of merger consideration on pro rata portion		$ 500,000
Juvenescence Limited [Member] | Loan Facility Agreement [Member]
Line of credit facility				$ 4,500,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 15, 2021	Mar. 06, 2021	Apr. 08, 2018	Sep. 30, 2018	Mar. 31, 2021	Mar. 31, 2020
Revenues					$ 56,000	$ 89,000
Grant Revenues [Member]
Revenues			$ 386,000		46,000	86,000
LifeMap Sciences [Member] | Subscription and Advertisement Revenues [Member]
Revenues					267,000	338,000
National Institutes of Health [Member] | For Treating Osteoporosis [Member]
Allowable expenses of grant revenues						25,000
National Institutes of Health [Member] | For Treating Stroke [Member]
Allowable expenses of grant revenues					$ 46,000	$ 61,000
National Institutes of Health [Member] | Grant Revenues [Member]
Revenues				$ 225,000
Merger Agreement [Member]
Indebtedness cash	$ 1,761,926	$ 1,761,296
Merger Agreement [Member] | ReCyte Therapeutics, Inc. [Member]
Ownership interest	94.80%

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount		2,851,000	2,846,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	[1]	3,431,000	150,000
Restricted Stock Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount		27,000	47,000
[1]	AgeX issued Juvenescence warrants to purchase 3,512,098 shares of AgeX common stock as consideration for the line of credit under the Loan Agreements discussed in Note 5.

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) - shares	Mar. 31, 2021	Mar. 31, 2020
Juvenescence Limited [Member] | Loan Agreement [Member]
Warrants to purchase common stock	3,512,098	3,512,098

Disposition and Deconsolidati_3

Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) - Merger Agreement [Member] - USD ($)	Mar. 15, 2021	Mar. 06, 2021
Payment of merger consideration on pro rata portion		$ 466,400
Indebtedness cash	$ 1,761,926	1,761,296
Conversion of shares of common stock, value		250,000
LifeMap Sciences [Member]
Payment of merger consideration on pro rata portion		$ 500,000

Disposition and Deconsolidati_4

Disposition and Deconsolidation of LifeMap Sciences - Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Net revenues		$ 56	$ 89
Loss from discontinued operations		(103)	(189)
Net loss from discontinued operations attributable to noncontrolling interest		(7)	(35)
Discontinued Operations [Member]
Net revenues		277	426
Costs, operating and other expenses		(380)	(615)
Loss from discontinued operations		(103)	(189)
Net loss from discontinued operations attributable to noncontrolling interest		7	35
Loss from discontinued operations	[1]	$ (96)	$ (154)
[1]	Does not include $106,000 gain on the deconsolidation of LifeMap Sciences recognized by AgeX. When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement line item Net (gain) loss on sales of businesses and assets. There were no gains or losses resulting from the sale of businesses or assets that did not meet the criteria for a discontinued operation during the three month periods ending March 31, 2021 and 2020.

Disposition and Deconsolidati_5

Disposition and Deconsolidation of LifeMap Sciences - Schedule of Discontinued Operations (Details) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Gain on deconsolidation of LifeMap Sciences	$ 106
Discontinued Operations [Member]
Gain on deconsolidation of LifeMap Sciences	$ 106

Selected Balance Sheet Compon_3

Selected Balance Sheet Components (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation and amortization expense	$ 227	$ 227
Amortization of intangible assets	33	33
Discontinued Operations [Member]
Amortization of intangible assets	$ 89	$ 107

Selected Balance Sheet Compon_4

Selected Balance Sheet Components - Schedule of Property and Equipment, Net, and Construction in Progress (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Equipment, furniture and fixtures	$ 381	$ 381
Accumulated depreciation and amortization	(381)	(381)
Property and equipment, net

Selected Balance Sheet Compon_5

Selected Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2021	[1]	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Intangible assets	$ 1,312		$ 5,586
Accumulated amortization	(344)		(3,994)
Total Intangible assets, net	$ 968		$ 1,592
[1]	Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Selected Balance Sheet Compon_6

Selected Balance Sheet Components - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	[1]	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Accounts payable	$ 370		$ 761
Accrued compensation	212		228
Accrued vendors and other expenses	616		667
Accounts payable and accrued liabilities	$ 1,198		$ 1,656
[1]	Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Feb. 10, 2021	Jan. 31, 2021	Mar. 30, 2020	Aug. 13, 2019	Oct. 31, 2018	Mar. 31, 2021
Value of common stock shares issued						$ 475,000
Chief Operating Officer [Member]
Transactions fixed annual amount					$ 280,000
New Loan Agreement [Member]
Line of credit, maximum borrowing capacity			$ 8,000,000
Line of credit, term			18 months
Stock issued during period, shares			28,500
Additional loan amount			$ 1,000,000
Line of credit, expiration date			Mar. 30, 2023
New Loan Agreement [Member] | Juvenescence's Discretion [Member]
Line of credit, maximum borrowing capacity		$ 8,000,000	$ 1,000,000
Line of credit borrowed money in excess			500,000
Borrowed an aggregate amount			$ 3,000,000
Additional loan amount		$ 2,000,000
Line of credit, expiration date		Mar. 30, 2023
Default amount		$ 1,000,000
2019 Loan Agreement [Member] | Juvenescence [Member]
Line of credit, term				18 months
Line of credit borrowed money in excess				$ 100,000
Additional loan amount	$ 1,000,000
Line of credit, expiration date	Feb. 14, 2022
Related party transaction description	Under those limits (a) the number of shares of common stock that may be issued upon conversion of any loan advance, at a conversion price that is lower than the market price of AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence's ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding.			On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the "2019 Loan Agreement") pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit
Line of credit facility				$ 2,000,000
Increase in line of credit	$ 4,000,000
Number of common stock shares issued				19,000
Value of common stock shares issued				$ 56,000
Related party transaction percent				10.00%
Gross proceeds from sale of common stock				$ 7,500,000
Line of credit borrowed money in excess not paid	2,000,000			$ 25,000
Origination Fee	$ 160,000
Warrants to purchase of common stock				150,000
Warrants exercise price				$ 2.60
Warrants, value				$ 236,000
Number of shares issuable				19,000
Issuance of warrants				150,000
Registration Rights Agreement [Member] | Juvenescence's Discretion [Member]
Registrable securities		19,695,746

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	Jan. 08, 2021	Aug. 13, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Preferred stock, shares authorized			5,000,000		5,000,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized			100,000,000		100,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares issued			37,935,000		37,691,000
Common stock, shares outstanding			37,935,000		37,691,000
Aggregate offering price of common stock			$ 475,000
Proceeds from sale of common stock			496,000
Juvenescence [Member] | 2019 Loan Agreement [Member]
Sale of warrants purchase of common stock		150,000
Number of common stock shares issued		19,000
Aggregate offering price of common stock		$ 56,000
Chardan Capital Markets LLC [Member]
Common stock, par value	$ 0.0001
Aggregate offering price of common stock	$ 12,600,000
Proceeds from sale of common stock			496,000
Warrants [Member]
Proceeds from loans			$ 7,500,000
Sale of warrants purchase of common stock			3,362,098
Number of common stock shares issued			28,500

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Summary of Reconciliation Changes in Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Balance	$ (5,396)	$ 2,617
Issuance of common stock	475
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes	(3)	(5)
Issuance of warrants	757
Stock-based compensation	182	260
Taransactions with noncontrolling interests - LifeMap Sciences
Deconsolidation of LifeMap Sciences	(22)
Foreign currency translation adjustment		(25)
Net loss	(2,096)	(3,222)
Balance	(6,103)	(375)
Common Stock [Member]
Balance	$ 4	$ 4
Balance, shares	37,691,000	37,649,000
Issuance of common stock
Issuance of common stock, shares	242,000
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	2,000	7,000
Issuance of warrants
Stock-based compensation
Taransactions with noncontrolling interests - LifeMap Sciences
Deconsolidation of LifeMap Sciences
Foreign currency translation adjustment
Net loss
Balance	$ 4	$ 4
Balance, shares	37,935,000	37,656,000
Additional Paid-In Capital [Member]
Balance	$ 91,810	$ 88,353
Issuance of common stock	475
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes	(3)	(5)
Issuance of warrants	757
Stock-based compensation	182	260
Taransactions with noncontrolling interests - LifeMap Sciences	(269)
Deconsolidation of LifeMap Sciences	143
Foreign currency translation adjustment
Net loss
Balance	93,095	88,608
Accumulated Deficit [Member]
Balance	(97,073)	(86,208)
Issuance of common stock
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes
Issuance of warrants
Stock-based compensation
Taransactions with noncontrolling interests - LifeMap Sciences
Deconsolidation of LifeMap Sciences
Foreign currency translation adjustment
Net loss	(2,088)	(3,187)
Balance	(99,161)	(89,395)
Noncontrolling Interest [Member]
Balance	(280)	399
Issuance of common stock
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes
Issuance of warrants
Stock-based compensation
Taransactions with noncontrolling interests - LifeMap Sciences	269
Deconsolidation of LifeMap Sciences	(22)
Foreign currency translation adjustment
Net loss	(8)	(35)
Balance	(41)	364
Accumulated Other Comprehensive Income [Member]
Balance	143	69
Issuance of common stock
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes
Issuance of warrants
Stock-based compensation
Taransactions with noncontrolling interests - LifeMap Sciences
Deconsolidation of LifeMap Sciences	(143)
Foreign currency translation adjustment		(25)
Net loss
Balance		$ 44

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Number of options exercised
Stock-based compensation expense recognized under discontinued operations	$ 4,000	$ 7,000
Number of options granted
2017 Equity Incentive Plan [Member]
Number of common stock reserved	4,000,000

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock Option Activity (Details) - Equity Incentive Plan [Member] - Stock Option [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	1,046,000
Shares Available for Grant, Options forfeited	14,000
Shares Available for Grant, Restricted stock units vested
Shares Available for Grant, Ending balance	1,060
Number of Options Outstanding, Beginning balance	2,854,000
Number of Options Outstanding, Options forfeited	(14,000)
Number of Options Outstanding, Restricted stock units vested
Number of Options Outstanding, Ending balance	2,840,000
Number of Options Outstanding, Exercisable, Ending balance	2,035,000
Number of RSUs Outstanding, Beginning balance	28,000
Number of RSUs Outstanding, Options forfeited
Number of RSUs Outstanding, Restricted stock units vested	(3,000)
Number of RSUs Outstanding, Ending balance	25,000
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 2.51
Weighted Average Exercise Price, Options forfeited | $ / shares	3
Weighted Average Exercise Price, Restricted stock units vested | $ / shares
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares	2.51
Weighted Average Exercise Price, Exercisable, Ending balance | $ / shares	$ 2.61

Stock-Based Awards - Schedule o

Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 178	$ 252
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	16	33
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 162	$ 220

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2021
GILTI [Member]
Income tax rate deduction	50.00%

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule Non-cash Investing and Financing Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for interest	$ 7	$ 7
Issuance of common stock upon vesting of restricted stock units (Note 6)	6	11
Issuance of warrants for debt issuance	$ 757

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jun. 02, 2020	Apr. 13, 2020USD ($)	Apr. 02, 2019USD ($)ft²	Mar. 31, 2021USD ($)ft²	Dec. 31, 2019USD ($)ft²	Apr. 30, 2019USD ($)
Notice of Delisting	AgeX received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange's continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the "Compliance Plan") advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange's continued listing standards by December 1, 2021. The Exchange staff has accepted the Compliance Plan.
Axos Bank [Member] | Paycheck Protection Program [Member]
Loan obtained		$ 432,952
Interest rate		1.00%
Loan maturity date		Apr. 13, 2022
Accounting Standards Update 2016-02 [Member]
Right-of-use asset						$ 726,000
Right-of-use liability						$ 726,000
Lease Agreement [Member]
Area of land | ft²			23,911	135
Base rent			$ 35,867	$ 947
Increase in base rent			$ 36,943
Lease expiration			Dec. 31, 2020
Tenant improvement expenses					$ 436,000
SubLease Agreement [Member]
Area of land | ft²					11,121
Base rent					$ 16,312
Lease expiration					Dec. 31, 2020
SubLease Agreement [Member] | First Sublessee [Member]
Base rent					$ 3,089
SubLease Agreement [Member] | Second Sublessee [Member]
Base rent					$ 15,405

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Amendment to 2019 Loan Agreement [Member] - Juvenescence [Member]	Apr. 23, 2021USD ($)
Additional loan amount	$ 500,000
Expiration date	Feb. 14, 2022